Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654 at the 64th ASH Annual Meeting & Exposition

November 30, 2022

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, announced preliminary clinical data for investigational agent TP-3654 will be presented at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held December 10-13 in New Orleans, Louisiana. The data will be shared in an oral podium presentation during the Myeloproliferative Syndromes: Clinical and Epidemiological: Latest Data for Combination and Emerging Targeted Therapies in Myelofibrosis session on December 10 at 3:15 p.m. CST. 

“We are excited to present data evaluating the potential of TP-3654 in advancing the treatment of patients with myelofibrosis,” said Patricia S. Andrews, CEO and Global Head of Oncology, Sumitomo Pharma Oncology, Inc. “These data reflect our relentless commitment to propelling drug discovery in oncology and our progress in advancing research in hematologic and solid malignancies.” 

TP-3654 is currently being evaluated in a Phase 1/2 study of oral TP-3654 in patients with intermediate and high-risk myelofibrosis, which is being conducted in the United States and Japan. To learn more about the study and eligibility for enrollment, visit clinicaltrials.gov (NCT04176198).

###